Characterization and Treatment of Inflammation and Insulin Resistance in Obese Adipose Tissue

References

• Sung H, Siegel RL, Torre LA, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2019;69(2):88–112.
   PubMed Web of Science ®Google Scholar
• Andersen LB, Mota J, Di Pietro L. Update on the global pandemic of physical inactivity. Lancet. 2016;388(10051):1255–1256. doi:10.1016/S0140-6736(16)30960-6
   PubMed Web of Science ®Google Scholar
• Tomiyama AJ. Stress and obesity. Ann Rev Psychol. 2019;70(1):703–718. doi:10.1146/annurev-psych-010418-102936
   PubMed Web of Science ®Google Scholar
• Yang C, Kong APS, Cai Z, Chung ACK. Persistent organic pollutants as risk factors for obesity and diabetes. Curr Diab Rep. 2017;17(12).
   PubMedGoogle Scholar
• WHO. Obesity and overweight fact sheet; 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
   Google Scholar
• Murtagh E. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–2642.
   PubMedGoogle Scholar
• Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer–viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794–798. doi:10.1056/NEJMsr1606602
   PubMed Web of Science ®Google Scholar
• Gadde KM, Martin CK, Berthoud H-R, Heymsfield SB. Obesity pathophysiology and management. J Am Coll Cardiol. 2018;71(1):69–84. doi:10.1016/j.jacc.2017.11.011
   PubMed Web of Science ®Google Scholar
• Greco F, Mallio CA, Grippo R, et al. Increased visceral adipose tissue in male patients with non-clear cell renal cell carcinoma. Radiol Med. 2020;125(6):538–543. doi:10.1007/s11547-020-01146-6
   PubMed Web of Science ®Google Scholar
• Greco F, Quarta LG, Grasso RF, Beomonte Zobel B, Mallio CA. Increased visceral adipose tissue in clear cell renal cell carcinoma with and without peritumoral collateral vessels. Br J Radiol. 2020;93(1112):20200334. doi:10.1259/bjr.20200334
   PubMed Web of Science ®Google Scholar
• Matrone A, Ferrari F, Santini F, Elisei R. Obesity as a risk factor for thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2020;27(5):358–363. doi:10.1097/MED.0000000000000556
   PubMedGoogle Scholar
• Silveira EA, Kliemann N, Noll M, Sarrafzadegan N, de Oliveira C. Visceral obesity and incident cancer and cardiovascular disease: an integrative review of the epidemiological evidence. Obes Rev. 2020. doi:10.1111/obr.13088
   PubMedGoogle Scholar
• Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world–a growing challenge. N Engl J Med. 2007;356(3):213–215. doi:10.1056/NEJMp068177
   PubMed Web of Science ®Google Scholar
• Jiang G, Luk AO, Tam CHT, et al. Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: a cohort study using the Hong Kong diabetes register and Hong Kong diabetes biobank. PLoS Med. 2020;17(7):e1003209. doi:10.1371/journal.pmed.1003209
   PubMedGoogle Scholar
• Pellegrinelli V, Carobbio S, Vidal-Puig A. Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. Diabetologia. 2016;59(6):1075–1088. doi:10.1007/s00125-016-3933-4
   PubMed Web of Science ®Google Scholar
• Giralt M, Villarroya F. White, brown, beige/brite: different adipose cells for different functions? Endocrinology. 2013;154(9):2992–3000. doi:10.1210/en.2013-1403
   PubMed Web of Science ®Google Scholar
• Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:22.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med. 2013;34(1):1–11. doi:10.1016/j.mam.2012.10.001
   PubMed Web of Science ®Google Scholar
• Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350(25):2549–2557. doi:10.1056/NEJMoa033179
   PubMed Web of Science ®Google Scholar
• Hocking SL, Stewart RL, Brandon AE, et al. Subcutaneous fat transplantation alleviates diet-induced glucose intolerance and inflammation in mice. Diabetologia. 2015;58(7):1587–1600. doi:10.1007/s00125-015-3583-y
   PubMed Web of Science ®Google Scholar
• Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360(15):1509–1517. doi:10.1056/NEJMoa0810780
   PubMed Web of Science ®Google Scholar
• Ravussin E, Galgani JE. The implication of brown adipose tissue for humans. Annu Rev Nutr. 2011;31(1):33–47. doi:10.1146/annurev-nutr-072610-145209
   PubMedGoogle Scholar
• Sidossis L, Kajimura S. Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. J Clin Invest. 2015;125(2):478–486. doi:10.1172/JCI78362
   PubMed Web of Science ®Google Scholar
• Sepa-Kishi DM, Ceddia RB. White and beige adipocytes: are they metabolically distinct? Horm Mol Biol Clin Investig. 2018;33(2). doi:10.1515/hmbci-2018-0003
   PubMedGoogle Scholar
• Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 2014;1842(3):446–462. doi:10.1016/j.bbadis.2013.05.017
   PubMed Web of Science ®Google Scholar
• Oishi Y, Manabe I. Macrophages in inflammation, repair and regeneration. Int Immunol. 2018;30(11):511–528.
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky J, Tordjman J, Poitou C, et al. Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab. 2009;94(11):4619–4623. doi:10.1210/jc.2009-0925
   PubMed Web of Science ®Google Scholar
• Russo L, Lumeng CN. Properties and functions of adipose tissue macrophages in obesity. Immunology. 2018;155(4):407–417. doi:10.1111/imm.13002
   PubMed Web of Science ®Google Scholar
• Qiu Y, Nguyen KD, Odegaard JI, et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell. 2014;157(6):1292–1308. doi:10.1016/j.cell.2014.03.066
   PubMed Web of Science ®Google Scholar
• Kosteli A, Sugaru E, Haemmerle G, et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest. 2010;120(10):3466–3479. doi:10.1172/JCI42845
   PubMed Web of Science ®Google Scholar
• Ferrante AW Jr. The immune cells in adipose tissue. Diabetes Obes Metab. 2013;15(Suppl 3):34–38. doi:10.1111/dom.12154
   PubMedGoogle Scholar
• Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46(11):2347–2355. doi:10.1194/jlr.M500294-JLR200
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–184. doi:10.1172/JCI29881
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–1830.
   PubMed Web of Science ®Google Scholar
• Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications–a review. Nutr J. 2014;13(1):17. doi:10.1186/1475-2891-13-17
   PubMedGoogle Scholar
• Oestreich KJ, Weinmann AS. Master regulators or lineage-specifying? Changing views on CD4+ T cell transcription factors. Nat Rev Immunol. 2012;12(11):799–804. doi:10.1038/nri3321
   PubMed Web of Science ®Google Scholar
• Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15(8):921–929. doi:10.1038/nm.2001
   PubMed Web of Science ®Google Scholar
• Winer DA, Winer S, Shen L, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med. 2011;17(5):610–617. doi:10.1038/nm.2353
   PubMed Web of Science ®Google Scholar
• Ahmed M, Gaffen SL. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev. 2010;21(6):449–453. doi:10.1016/j.cytogfr.2010.10.005
   PubMed Web of Science ®Google Scholar
• DeFuria J, Belkina AC, Jagannathan-Bogdan M, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A. 2013;110(13):5133–5138. doi:10.1073/pnas.1215840110
   PubMed Web of Science ®Google Scholar
• Blaszczak AM, Bernier M, Wright VP, et al. Obesogenic memory maintains adipose tissue inflammation and insulin resistance. Immunometabolism. 2020;2(3).
   PubMedGoogle Scholar
• Toubal A, Kiaf B, Beaudoin L, et al. Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity. Nat Commun. 2020;11(1):3755. doi:10.1038/s41467-020-17307-0
   PubMed Web of Science ®Google Scholar
• Khan S, Tsai S, Winer DA. Adipose tissue B cells come of age: the AABs of fat inflammation. Cell Metab. 2019;30(6):997–999. doi:10.1016/j.cmet.2019.11.007
   PubMedGoogle Scholar
• Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res. 2017;113(9):1009–1023.
   PubMed Web of Science ®Google Scholar
• Frasca D, Diaz A, Romero M, Thaller S, Blomberg BB. Secretion of autoimmune antibodies in the human subcutaneous adipose tissue. PLoS One. 2018;13(5):e0197472. doi:10.1371/journal.pone.0197472
   PubMed Web of Science ®Google Scholar
• Bolus WR, Kennedy AJ, Hasty AH. Obesity‐induced reduction of adipose eosinophils is reversed with low‐calorie dietary intervention. Physiol Rep. 2018;6(22):22. doi:10.14814/phy2.13919
   Google Scholar
• Wu D, Molofsky AB, Liang HE, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011;332(6026):243–247. doi:10.1126/science.1201475
   PubMed Web of Science ®Google Scholar
• Knights AJ, Vohralik EJ, Houweling PJ, et al. Eosinophil function in adipose tissue is regulated by Krüppel-like factor 3 (KLF3). Nat Commun. 2020;11(1):1–12. doi:10.1038/s41467-020-16758-9
   PubMedGoogle Scholar
• Watanabe Y, Nagai Y, Honda H, et al. Bidirectional crosstalk between neutrophils and adipocytes promotes adipose tissue inflammation. FASEB J. 2019;33(11):11821–11835.
   PubMedGoogle Scholar
• Tam TH, Chan KL, Boroumand P, et al. Nucleotides released from palmitate-activated murine macrophages attract neutrophils. J Biol Chem. 2020;295(15):4902–4911. doi:10.1074/jbc.RA119.010868
   PubMedGoogle Scholar
• Bertola A, Ciucci T, Rousseau D, et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes. 2012;61(9):2238–2247. doi:10.2337/db11-1274
   PubMed Web of Science ®Google Scholar
• Stefanovic-Racic M, Yang X, Turner MS, et al. Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c+ cells in adipose tissue and liver. Diabetes. 2012;61(9):2330–2339.
   PubMedGoogle Scholar
• Zhou Y, Yu X, Chen H, et al. Leptin deficiency shifts mast cells toward anti-inflammatory actions and protects mice from obesity and diabetes by polarizing M2 macrophages. Cell Metab. 2015;22(6):1045–1058. doi:10.1016/j.cmet.2015.09.013
   PubMed Web of Science ®Google Scholar
• Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med. 2009;15(8):940–945. doi:10.1038/nm.1994
   PubMed Web of Science ®Google Scholar
• Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl. 2012;6(1‐2):91–101.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JMJN. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–432. doi:10.1038/372425a0
   PubMed Web of Science ®Google Scholar
• Hube F, Lietz U, Igel M, et al. Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Horm Metab Res. 1996;28(12):690–693. doi:10.1055/s-2007-979879
   PubMedGoogle Scholar
• Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–295.
   PubMed Web of Science ®Google Scholar
• Leshan RL, Bjornholm M, Munzberg H, Myers MG Jr. Leptin receptor signaling and action in the central nervous system. Obesity (Silver Spring). 2006;14(Suppl 5):208s–212s. doi:10.1038/oby.2006.310
   PubMedGoogle Scholar
• Pan W, Allison MB, Sabatini P, et al. Transcriptional and physiological roles for STAT proteins in leptin action. Mol Metab. 2019;22:121–131. doi:10.1016/j.molmet.2019.01.007
   PubMedGoogle Scholar
• Minokoshi Y, Kim Y-B, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415(6869):339–343. doi:10.1038/415339a
   PubMed Web of Science ®Google Scholar
• Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70(1):537–556. doi:10.1146/annurev.physiol.70.113006.100707
   PubMed Web of Science ®Google Scholar
• Mai S, Walker GE, Vietti R, et al. Acute vitamin D(3) supplementation in severe obesity: evaluation of multimeric adiponectin. Nutrients. 2017;9(5):459. doi:10.3390/nu9050459
   PubMedGoogle Scholar
• Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen BJM. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004;219(1–2):9–15. doi:10.1016/j.mce.2004.03.002
   PubMedGoogle Scholar
• Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746–26749. doi:10.1074/jbc.270.45.26746
   PubMed Web of Science ®Google Scholar
• Leal VdO MD. Adipokines in obesity. Clin Chim Acta. 2013;419:87–94.
   PubMedGoogle Scholar
• Liu W, Zhou X, Li Y, et al. Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus: a population-based study. Medicine. 2020;99(6):e19052. doi:10.1097/MD.0000000000019052
   PubMed Web of Science ®Google Scholar
• Tsiotra PC, Tsigos C, Anastasiou E, et al. Peripheral mononuclear cell resistin mRNA expression is increased in type 2 diabetic women. Mediators Inflamm. 2008;2008:892864. doi:10.1155/2008/892864
   PubMed Web of Science ®Google Scholar
• Nagaev I, Bokarewa M, Tarkowski A, Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One. 2006;1(1):e31. doi:10.1371/journal.pone.0000031
   PubMedGoogle Scholar
• Yang R-Z, Lee M-J, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006;290(6):E1253–E1261. doi:10.1152/ajpendo.00572.2004
   PubMed Web of Science ®Google Scholar
• Elsaid NH, Sadik NA, Ahmed NR, Fayez SE, Mohammed NAE-G. Serum omentin-1 levels in type 2 diabetic obese women in relation to glycemic control, insulin resistance and metabolic parameters. J Clin Transl Endocrinol. 2018;13:14–19. doi:10.1016/j.jcte.2018.05.003
   PubMedGoogle Scholar
• Zhong X, Li X, Liu F, Tan H, Shang DJB. Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway. Biochem Biophys Res Commun. 2012;425(2):401–406.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu F, Han F, Lv L, Tang CE, Luo F. Omentin-1 ameliorated free fatty acid-induced impairment in proliferation, migration, and inflammatory states of HUVECs. Cardiol Res Pract. 2020;2020:3054379. doi:10.1155/2020/3054379
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91. doi:10.1126/science.7678183
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409–2415. doi:10.1172/JCI117936
   PubMed Web of Science ®Google Scholar
• Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–377.
   PubMed Web of Science ®Google Scholar
• Stanley TL, Zanni MV, Johnsen S, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011;96(1):E146–150. doi:10.1210/jc.2010-1170
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–1808. doi:10.1172/JCI200319246
   PubMed Web of Science ®Google Scholar
• Maachi M, Pieroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNF α, leptin and IL-6 levels in obese women. Int J Obes. 2004;28(8):993–997. doi:10.1038/sj.ijo.0802718
   PubMed Web of Science ®Google Scholar
• Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129–139. doi:10.1016/j.mce.2009.08.018
   PubMed Web of Science ®Google Scholar
• Timper K, Denson JL, Steculorum SM, et al. IL-6 improves energy and glucose homeostasis in obesity via enhanced central IL-6 trans-signaling. Cell Rep. 2017;19(2):267–280. doi:10.1016/j.celrep.2017.03.043
   PubMed Web of Science ®Google Scholar
• Ray I, Mahata SK, De RK. Obesity: an immunometabolic perspective. Front Endocrinol (Lausanne). 2016;7:157. doi:10.3389/fendo.2016.00157
   PubMedGoogle Scholar
• Nishimoto S, Fukuda D, Higashikuni Y, et al. Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance. Sci Adv. 2016;2(3):e1501332.
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006;116(1):115–124. doi:10.1172/JCI24335
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang X, Deng B, Xiao J, Jin J, Huang Z. Lipopolysaccharide and palmitic acid synergistically induced MCP-1 production via MAPK-meditated TLR4 signaling pathway in RAW264.7 cells. Lipids Health Dis. 2019;18(1):71. doi:10.1186/s12944-019-1017-4
   PubMedGoogle Scholar
• Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes. 2005;29(1):146–150. doi:10.1038/sj.ijo.0802839
   Google Scholar
• Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14(3):R141.
   PubMed Web of Science ®Google Scholar
• van den Oever IAM, Baniaamam M, Simsek S, et al. The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. Rheumatol Int. 2020. doi:10.1007/s00296-020-04666-6
   PubMedGoogle Scholar
• Sun X, Han F, Yi J, Han L, Wang B. Effect of aspirin on the expression of hepatocyte NF-kappaB and serum TNF-alpha in streptozotocin-induced type 2 diabetic rats. J Korean Med Sci. 2011;26(6):765–770. doi:10.3346/jkms.2011.26.6.765
   PubMedGoogle Scholar
• Ferraz-Amaro I, Arce-Franco M, Muniz J, et al. Systemic blockade of TNF-alpha does not improve insulin resistance in humans. Horm Metab Res. 2011;43(11):801–808. doi:10.1055/s-0031-1287783
   PubMed Web of Science ®Google Scholar
• Leporini C, Russo E. Insulin-sensiting effects of tumor necrosis factor alpha inhibitors in rheumatoid arthritis: a systematic review and meta-analysis. Rev Recent Clin Trials. 2018;13(3):184–191. doi:10.2174/1574887113666180314100340
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Masedu F, Alvaro S, et al. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): a multicentre, open-label, randomised controlled trial. PLoS Med. 2019;16(9):e1002901. doi:10.1371/journal.pmed.1002901
   PubMed Web of Science ®Google Scholar
• Castaneda S, Remuzgo-Martinez S, Lopez-Mejias R, et al. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):465–473.
   PubMedGoogle Scholar
• Bako HY, Ibrahim MA, Isah MS, Ibrahim S. Inhibition of JAK-STAT and NF-kappaB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes. Life Sci. 2019;239:117045. doi:10.1016/j.lfs.2019.117045
   PubMed Web of Science ®Google Scholar
• Ge Z, Zhang P, Hong T, et al. Erythropoietin alleviates hepatic insulin resistance via PPARgamma-dependent AKT activation. Sci Rep. 2015;5(1):17878. doi:10.1038/srep17878
   PubMedGoogle Scholar
• Zhang H, Ge Z, Tang S, Meng R, Bi Y, Zhu D. Erythropoietin ameliorates PA-induced insulin resistance through the IRS/AKT/FOXO1 and GSK-3beta signaling pathway, and inhibits the inflammatory response in HepG2 cells. Mol Med Rep. 2017;16(2):2295–2301. doi:10.3892/mmr.2017.6810
   PubMedGoogle Scholar
• Wolfe BM, Kvach E, Eckel RH. Treatment of obesity: weight loss and bariatric surgery. Circ Res. 2016;118(11):1844–1855. doi:10.1161/CIRCRESAHA.116.307591
   PubMed Web of Science ®Google Scholar
• Panel NIoHCD. Gastrointestinal surgery for severe obesity. Ann Intern Med. 1991;115:956–961.
   PubMedGoogle Scholar
• Hanipah ZN, Schauer PR. Bariatric surgery as a long-term treatment for type 2 diabetes/metabolic syndrome. Annu Rev Med. 2020;71:1–15.
   PubMedGoogle Scholar
• Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018;39(2):79–132.
   PubMed Web of Science ®Google Scholar
• English WJ, DeMaria EJ, Hutter MM, et al. American society for metabolic and bariatric surgery 2018 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 2020;16(4):457–463. doi:10.1016/j.soard.2019.12.022
   PubMed Web of Science ®Google Scholar
• Sjostrom L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes. 2008;32(Suppl 7):S93–97. doi:10.1038/ijo.2008.244
   Web of Science ®Google Scholar
• Jouan Y, Blasco H, Bongrani A, Couet C, Dupont J, Maillot F. Preoperative chemerin level is predictive of inflammatory status 1 year after bariatric surgery. Obes Surg. 2020;30(10):3852–3861. doi:10.1007/s11695-020-04584-3
   PubMedGoogle Scholar
• Faramia J, Ostinelli G, Drolet-Labelle V, Picard F, Tchernof A. Metabolic adaptations after bariatric surgery: adipokines, myokines and hepatokines. Curr Opin Pharmacol. 2020;52:67–74. doi:10.1016/j.coph.2020.06.005
   PubMed Web of Science ®Google Scholar
• Sala P, Torrinhas R, Fonseca DC, et al. Intestinal expression of toll-like receptor gene changes early after gastric bypass surgery and association with type 2 diabetes remission. Nutrition. 2020;79–80:110885. doi:10.1016/j.nut.2020.110885
   PubMed Web of Science ®Google Scholar
• Salman MA, Salman AA, Nafea MA, et al. Study of changes of obesity-related inflammatory cytokines after laparoscopic sleeve gastrectomy. ANZ J Surg. 2019;89(10):1265–1269. doi:10.1111/ans.15427
   PubMed Web of Science ®Google Scholar
• Min T, Prior SL, Dunseath G, Churm R, Barry JD, Stephens JW. Temporal effects of bariatric surgery on adipokines, inflammation and oxidative stress in subjects with impaired glucose homeostasis at 4 years of follow-up. Obes Surg. 2020;30(5):1712–1718. doi:10.1007/s11695-019-04377-3
   PubMed Web of Science ®Google Scholar
• Kerr AG, Andersson DP, Rydén M, Arner P, Dahlman I. Long-term changes in adipose tissue gene expression following bariatric surgery. J Intern Med. 2020;288(2):219–233. doi:10.1111/joim.13066
   PubMedGoogle Scholar
• Lee Y-H, Hsiao H-F, Yang H-T, Huang S-Y, Chan WP. Reproducibility and repeatability of computer tomography-based measurement of abdominal subcutaneous and visceral adipose tissues. Sci Rep. 2017;7(1):40389. doi:10.1038/srep40389
   PubMedGoogle Scholar
• Bjorndal B, Burri L, Staalesen V, Skorve J, Berge RK. Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J Obes. 2011;2011:490650. doi:10.1155/2011/490650
   PubMedGoogle Scholar
• Shen W, Wang Z, Punyanita M, et al. Adipose tissue quantification by imaging methods: a proposed classification. Obes Res. 2003;11(1):5–16. doi:10.1038/oby.2003.3
   PubMedGoogle Scholar
• Cuevas-Ramos D, Almeda-Valdes P, Aguilar-Salinas CA, Cuevas-Ramos G, Cuevas-Sosa AA, Gomez-Perez FJ. The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism. Curr Diabetes Rev. 2009;5(4):216–220. doi:10.2174/157339909789804396
   PubMedGoogle Scholar
• Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020. doi:10.1038/s41574-020-0386-0
   PubMedGoogle Scholar
• Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46(5):860–867. doi:10.2337/diab.46.5.860
   PubMed Web of Science ®Google Scholar
• Hosaka S, Yamada T, Takahashi K, et al. Inhibition of plasminogen activator inhibitor-1 activation suppresses high fat diet-induced weight gain via alleviation of hypothalamic leptin resistance. Front Pharmacol. 2020;11:943. doi:10.3389/fphar.2020.00943
   PubMed Web of Science ®Google Scholar
• Zheng Z, Nakamura K, Gershbaum S, et al. Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity. J Clin Invest. 2020;10–1172.
   PubMedGoogle Scholar
• Liu M, Zhu H, Dai Y, et al. Zinc-α2-glycoprotein is associated with obesity in chinese people and HFD-induced obese mice. Front Physiol. 2018;9:62. doi:10.3389/fphys.2018.00062
   PubMedGoogle Scholar
• Severo JS, Morais JBS, Beserra JB, et al. Role of zinc in zinc-α2-glycoprotein metabolism in obesity: a review of literature. Biol Trace Elem Res. 2020;193(1):81–88. doi:10.1007/s12011-019-01702-w
   PubMedGoogle Scholar
• Rychter AM, Skrzypczak-Zielińska M, Zielińska A, et al. Is the retinol-binding protein 4 a possible risk factor for cardiovascular diseases in obesity? Int J Mol Sci. 2020;21(15):5229. doi:10.3390/ijms21155229
   PubMedGoogle Scholar
• Kilicarslan M, de Weijer BA, Simonyté Sjödin K, et al. RBP4 increases lipolysis in human adipocytes and is associated with increased lipolysis and hepatic insulin resistance in obese women. FASEB J. 2020;34(5):6099–6110. doi:10.1096/fj.201901979RR
   PubMed Web of Science ®Google Scholar
• Kelly KR, Kashyap SR, O’Leary VB, Major J, Schauer PR, Kirwan JP. Retinol-binding protein 4 (RBP4) protein expression is increased in omental adipose tissue of severely obese patients. Obesity (Silver Spring). 2010;18(4):663–666. doi:10.1038/oby.2009.328
   PubMedGoogle Scholar
• Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148(10):4687–4694. doi:10.1210/en.2007-0175
   PubMed Web of Science ®Google Scholar
• Karczewska-Kupczewska M, Nikołajuk A, Stefanowicz M, Matulewicz N, Kowalska I, Strączkowski M. Serum and adipose tissue chemerin is differentially related to insulin sensitivity. Endocr Connect. 2020;9(5):360–369. doi:10.1530/EC-20-0084
   PubMed Web of Science ®Google Scholar
• Heo YJ, Choi SE, Jeon JY, et al. Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes. J Diabetes Res. 2019;2019:4021623.
   PubMed Web of Science ®Google Scholar
• Nourbakhsh M, Nourbakhsh M, Gholinejad Z, Razzaghy-Azar M. Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome. Scand J Clin Lab Invest. 2015;75(2):183–188. doi:10.3109/00365513.2014.1003594
   PubMed Web of Science ®Google Scholar